MBBP Obtains First iPSC Notice of Allowance on Behalf of Whitehead Institute

Whitehead Institute for Biomedical ResearchMBBP has obtained a Notice of Allowance from the USPTO for Patent Application Number 10/997,146 entitled “Methods for Reprogramming Somatic Cells” on behalf of our client Whitehead Institute for Biomedical Research and exclusive licensee Fate Therapeutics. Upon issuance, the patent will cover foundational induced pluripotent stem cell technology for identifying agents that enable the reprogramming of human somatic cells; the application is believed to contain the earliest allowed claims in the US for induced pluripotent stem cell technology. Whitehead Institute is a leading, nonprofit research and educational institution defining the cutting edge of biomedical science, and Fate Therapeutics is a leader in stem cell and developmental biology research using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics.

For full press release, please visit Fate Therapeutics.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s